Maze Therapeutics (MAZE.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov13

Raymond James Analyst Assigns Buy Rating to Maze Therapeutics

21:37

Nov7

Maze Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue USD 0 and EPS USD -2.5752

04:00

Maze Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.66 (forecast USD -0.7099)

04:00

Nov6

Maze Therapeutics Updates Its Clinical Pipeline

21:03

Sep29

JPMorgan Raises Maze Therapeutics Price Target and Maintains Overweight Rating

13:00

H.C. Wainwright Reiterates Buy Rating for Maze Therapeutics with $50 Price Target

12:12

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -30.09 M, EPS -0.66

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -33.68 M, EPS -0.7699

May14

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -32.79 M, EPS -1.1452

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change